Dr Olivier Brandicourt, CEO, Sanofi (Photo Courtesy: www.handelsblatt.com)
Sanofi and the life sciences team at Google announced that they are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes.
The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design.
The companies will explore how to improve diabetes care by developing new tools that bring together many of the previously siloed pieces of diabetes management and enable new kinds of interventions.
This includes health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.
Both parties will combine their respective expertise in science and technology to work on better ways to collect, analyze and understand multiple sources of information impacting diabetes.
The hope is that it will be easier for patients to successfully manage their diabetes, which would reduce the risk of complications, improve outcomes and ultimately lower costs.
"As a global leader in diabetes care, we have both an obligation and a commitment to provide integrated solutions for people living with diabetes," said Dr Olivier Brandicourt, CEO, Sanofi. "This initiative combines Sanofi's strength and knowledge in diabetes with Google's leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care."
"We are experiencing a worldwide pandemic of diabetes, and it's very encouraging to see healthcare and technology innovators step up to the challenge of providing cutting edge tools and care advancing technologies to help people with diabetes manage their disease, 24/7," said Mr John L. Brooks, III, president and CEO, Joslin Diabetes Center, which is a partner to the collaboration. "Technology, sensors, analytics, and digital solutions will revolutionize how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care. Ultimately, I truly hope we're able to turn the Joslin Diabetes Center into a museum."